Showing 2251-2260 of 2314 results for "".
- Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Diseasehttps://modernod.com/news/novaliq-raises-new-capital-to-accelerate-the-commercialization-of-its-lead-products-for-dry-eye-disease/2479793/Novaliq announced it has raised $53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised $115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding, an active investor in Life and Health Scienc
- Alcon Expands Surgical Offerings with Portfolio of Mydriatic, Cycloplegic, Diagnostic, and Anesthetic Productshttps://modernod.com/news/alcon-expands-surgical-offerings-with-portfolio-of-mydriatic-cycloplegic-diagnostic-and-anesthetic-products/2479801/Alcon announced that it is expanding its surgical offerings with the addition of a group of products fundamental to many ophthalmic procedures done in the clinic and operating room. These products, which include mydriatic, cycloplegic, diagnostic, and anesthetic products, were transferred from Al
- ASCRS Releases Preliminary CyPass Withdrawal Consensus Statementhttps://modernod.com/news/ascrs-releases-preliminary-cypass-withdrawal-consensus-statement/2479843/The American Society of Cataract and Refractive Surgery convened a CyPass Withdrawal Task Force to review the data from the COMPASS-XT study and related research and develop an independent physician guidance document associated with the voluntary withdrawal of Alcon’s CyPass Micro-Stent. To
- Oxurion Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-enrolls-first-patient-in-phase-1-clinical-trial-evaluating-thr-687-for-treatment-of-dme/2479860/Oxurion announced the enrollment of the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME). THR-687 is a novel pan-RGD integrin antagoni
- Orbis and Visulytix Unveil Collaboration to Integrate AI Into Global Eye Health Effortshttps://modernod.com/news/orbis-and-visulytix-unveil-collaboration-to-integrate-ai-into-global-eye-health-efforts/2479903/Eye doctors in low-resource countries will receive sophisticated diagnostic technology thanks to a new collaboration between Orbis International, a nonprofit organization fighting global blindnes
- A Contact Lens Was Embedded in Woman’s Eyelid for 28 Yearshttps://modernod.com/news/a-contact-lens-was-embedded-in-womans-eyelid-for-28-years/2479936/Imagine going to the eye doctor because your upper eyelid is swollen and painful. The doctor tells you it’s a cyst and operates. Inside the blister, the surgeon finds a contact lens: a rigid gas-permeable one.
- Mount Sinai Researchers Discover How to Restore Vision Using Retinal Stem Cellshttps://modernod.com/news/mount-sinai-researchers-discover-how-to-restore-vision-using-retinal-stem-cells/2479939/Researchers at Mount Sinai have successfully restored vision in mice through activating retinal stem cells, something that has never been done before. Their study, published in the August 15 online issue of Nature, could transform treatment for patients with retinal degenerative diseases
- Aerie Pharmaceuticals Reports Topline Results From Rhopressa Mechanism of Action Studyhttps://modernod.com/news/aerie-pharmaceuticals-reports-topline-result-from-rhopressa-mechanism-of-action-study/2479942/Aerie Pharmaceuticals announced topline efficacy results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of Rhopressa (netarsudil ophthalmic solution 0.02%) on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. While seve
- RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarringhttps://modernod.com/news/rxi-pharmaceuticals-announces-positive-results-from-phase-1-2-trial-with-rxi-109-for-retinal-scarring/2479959/RXi Pharmaceuticals announced positive results with RXI-109 in a phase 1/2 clinical trial. RXI-109-1501 is an open-label, multidose, dose escalation study with three dose cohorts, enrolled sequentially, evaluating the safety and tolerability of RXI-109 injections in the eye of subjects with advan
- Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertensionhttps://modernod.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/Nicox announced the initiation of a phase 2 clinical study evaluating NCX 470, its novel, second-generation nitric oxide (NO)-donating prostaglandin analog, for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension by enrolling 10 patient